Oncodesign Services

Oncodesign Services is a leading contract research organization (CRO) specializing in drug discovery and preclinical research, with operations in France, Canada, and the United States.
This article provides an overview of the company’s preclinical contract research services and its extensive portfolio of disease models supporting translational drug development.

Features of Oncodesign Services’ Contract Services for Non-Clinical Studies

Expertise in Pharmacokinetics and Drug Metabolism (DMPK/ADME)

Oncodesign Services’ DMPK division conductscomprehensive studies in pharmacokinetics and drug metabolism (DMPK/ADME)for novel therapeutic candidates. Leveraging extensive experience across a wide range of drug discovery programs, the company delivers tailored and scientifically robust ADME/DMPK solutions to support informed decision-making throughout preclinical development.

Advanced Pharmacological and Molecular Imaging Capabilities

The company offersadvanced multimodal and nuclear imaging technologies, enabling detailed visualization of drug biodistribution, pharmacological efficacy, and biomarker responses in vivo. In addition, Oncodesign Services has strong expertise in molecular radiotherapy research, including radiolabeling of small molecules and antibodies, providing valuable insights into therapeutic targeting and mechanism of action.

In-house ABSL-2 and ABSL-3 Facilities

To address emerging infectious diseases that pose global public health threats, Oncodesign Services provides dedicated platforms supporting the development of therapeutic and preventive strategies.The company operates in-house ABSL-2 and ABSL-3 (Animal Biosafety Level) facilities, allowing studies involving high-risk pathogens such as SARS-CoV-2 and Mycobacterium tuberculosis.

Animal welfare is a core priority, and all in vivo studies are conducted under strict oversight in accordance with international ethical and regulatory guidelines.

Examples of Disease Models Available at Oncodesign Services

Oncodesign Services maintains a diverse portfolio of disease models designed to closely reflect human pathophysiology.
In the field of autoimmune disease research, the company offers both industry-standard and specialized models, including:
- Collagen-induced arthritis (CIA) models in mice and rats
- Acute experimental autoimmune encephalomyelitis (EAE) / multiple sclerosis (MS) models in mice
- Relapsing–remitting EAE / MS models in mice

In addition, the company provides preclinical CRO services focused on inflammatory liver diseases, including rodent models of hepatic inflammation.

Oncodesign Services Non-Clinical Case Study

Liver Fibrosis Research

The carbon tetrachloride (CCl₄)-induced liver fibrosis model is a widely established preclinical model. Repeated administration of CCl₄ to young mice typically induces liver fibrosis within approximately six weeks.

This model is well suited for evaluating therapeutic approaches targeting collagen deposition and regulation of matrix metalloproteinase expression. ALK5 inhibition, a well-characterized anti-fibrotic mechanism known to reduce collagen induction, is commonly used as a reference compound in these studies.

Oncodesign Services Company Information

Founded in 1955, Oncodesign Services isa global CRO focused on drug discovery and preclinical research.With operations in France, Canada, and the United States, the company supports the development of innovative therapies across oncology, immunology, inflammatory diseases, and infectious diseases.